» Articles » PMID: 25313448

Short Communication: Viremic Control is Independent of Repeated Low-dose SHIVSF162p3 Exposures

Overview
Publisher Mary Ann Liebert
Date 2014 Oct 15
PMID 25313448
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The repeat low-dose virus challenge model is commonly used in nonhuman primate studies of HIV transmission and biomedical preventions. For some viruses or challenge routes, it is uncertain whether the repeated exposure design might induce virus-directed innate or adaptive immunity that could affect infection or viremic outcomes. Retrospective cohorts of male Indian rhesus (n=40) and female pigtail (n=46) macaques enrolled in repeat low-dose rectal or vaginal SHIV(SF162p3) challenge studies, respectively, were studied to compare the relationship between the number of previous exposures and peak plasma SHIV RNA levels or viral load area under the curve (AUC), surrogate markers of viral control. Repeated mucosal exposures of 10 or 50 TCID50 of virus for rectal and vaginal exposures, respectively, were performed. Virus levels were measured by quantitative reverse-transcriptase real-time PCR. The cumulative number of SHIV(SF162p3) exposures did not correlate with observed peak virus levels or with AUC in rectally challenged rhesus macaques [peak: rho (ρ)=0.04, p=0.8; AUC: ρ=0.33, p=0.06] or vaginally challenged pigtail macaques (peak: ρ=-0.09, p=0.7; AUC: ρ=0.11, p=0.6). Infections in these models occur independently of exposure history and provide assurance that neither inoculation route nor number of exposures required for infection correlates with postinfection viremia. These data also indicate that both the vaginal and rectal repeated low-dose virus exposure models using SHIV(SF162p3) provide a reliable system for nonhuman primate studies.

Citing Articles

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models.

Khoury D, Wheatley A, Ramuta M, Reynaldi A, Cromer D, Subbarao K Nat Rev Immunol. 2020; 20(12):727-738.

PMID: 33139888 PMC: 7605490. DOI: 10.1038/s41577-020-00471-1.


Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs.

Cong M, Pau C, Heneine W, Garcia-Lerma J PLoS One. 2016; 11(11):e0164821.

PMID: 27806064 PMC: 5091888. DOI: 10.1371/journal.pone.0164821.


Animal models in HIV-1 protection and therapy.

Hessell A, Haigwood N Curr Opin HIV AIDS. 2015; 10(3):170-6.

PMID: 25730345 PMC: 4526147. DOI: 10.1097/COH.0000000000000152.

References
1.
Smith J, Rastogi R, Teller R, Srinivasan P, Mesquita P, Nagaraja U . Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A. 2013; 110(40):16145-50. PMC: 3791780. DOI: 10.1073/pnas.1311355110. View

2.
Kersh E, Luo W, Zheng Q, Adams D, Hanson D, Youngpairoj A . Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. J Infect Dis. 2012; 206(5):770-9. PMC: 3491742. DOI: 10.1093/infdis/jis422. View

3.
Otten R, Adams D, Kim C, Jackson E, Pullium J, Lee K . Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis. 2004; 191(2):164-73. DOI: 10.1086/426452. View

4.
Radzio J, Aung W, Holder A, Martin A, Sweeney E, Mitchell J . Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One. 2012; 7(12):e50632. PMC: 3514231. DOI: 10.1371/journal.pone.0050632. View

5.
Harouse J, Gettie A, Eshetu T, Tan R, Bohm R, Blanchard J . Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol. 2001; 75(4):1990-5. PMC: 115146. DOI: 10.1128/JVI.75.4.1990-1995.2001. View